PRDM10 Inhibitors
Chemical inhibitors of PRDM10 can act through various mechanisms that disrupt the protein's role in transcription regulation and chromatin remodeling. Staurosporine, for instance, is a potent protein kinase inhibitor, and by inhibiting kinases, it may disrupt downstream phosphorylation events that are crucial for PRDM10's activity. By blocking these phosphorylation pathways, staurosporine can inhibit the functional activation of PRDM10, which is necessary for its role as a transcription co-regulator. Similarly, alsterpaullone targets cyclin-dependent kinases (CDKs), which are pivotal in cell cycle progression and could be indirectly involved in the regulation of PRDM10 activity by affecting the transcriptional machinery and potentially preventing PRDM10 from undertaking its gene expression modulatory functions.
Inhibition of histone deacetylases (HDACs) represents another strategy to impede PRDM10 function. Compounds such as trichostatin A, entinostat, vorinostat, romidepsin, panobinostat, mocetinostat, and belinostat can increase histone acetylation levels, which may alter the chromatin landscape, potentially hindering PRDM10's ability to access or modify chromatin. This alteration in chromatin structure can inhibit PRDM10's ability to regulate gene expression effectively. On a similar note, chemicals like 5-azacytidine and RG108 inhibit DNA methyltransferases (DNMTs), leading to the hypomethylation of DNA. Since PRDM10 is implicated in the recognition or placement of epigenetic marks, such hypomethylation can disrupt the genomic contexts that PRDM10 operates within, thereby inhibiting its regulatory influence over gene expression. By targeting these specific enzymes that modify chromatin, these inhibitors can create an environment wherein PRDM10 cannot effectively exert its regulatory functions, leading to its functional inhibition.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Inhibits multiple protein kinases, which can result in the inhibition of PRDM10 by disrupting downstream phosphorylation events that are essential for PRDM10's functional activity as a transcription co-regulator. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Inhibits cyclin-dependent kinases (CDKs), which are involved in cell cycle progression. As PRDM10 is known to interact with transcriptional machinery, inhibition of CDKs can disrupt the cell cycle regulation and potentially prevent PRDM10 from fulfilling its role in gene expression control. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Inhibits histone deacetylases (HDACs). Since PRDM10 is a transcription co-regulator and HDACs modulate chromatin structure, the inhibition of HDACs can lead to increased acetylation of histones, thereby altering the chromatin landscape and potentially hindering PRDM10's ability to access or modify chromatin and regulate gene expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
Inhibits DNA methyltransferases (DNMTs), which could lead to hypomethylation of DNA. PRDM10 is implicated in transcription regulation and chromatin remodeling; therefore, changes in DNA methylation status can disrupt the genomic contexts in which PRDM10 operates, thereby inhibiting its functional activity. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $128.00 $505.00 | 2 | |
Another DNMT inhibitor that can lead to DNA hypomethylation, potentially disrupting the epigenetic marks that are recognized or placed by PRDM10, thereby inhibiting its role in gene regulation. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $88.00 $208.00 | 24 | |
A selective HDAC inhibitor, which can lead to changes in chromatin structure and function. By increasing acetylation levels, entinostat may indirectly inhibit PRDM10's ability to interact with chromatin, thereby inhibiting its role in regulating gene expression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
A potent HDAC inhibitor that can disrupt the chromatin modifications necessary for PRDM10 to exert its regulatory functions on gene expression. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $214.00 $622.00 | 1 | |
Another HDAC inhibitor, romidepsin can alter chromatin structure and potentially inhibit the interaction of PRDM10 with chromatin, thus inhibiting its transcriptional regulatory functions. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $196.00 | 9 | |
An HDAC inhibitor that can alter the epigenetic landscape, potentially hindering PRDM10's ability to regulate gene expression due to changes in chromatin accessibility and structure. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $210.00 $242.00 $1434.00 | 2 | |
An HDAC inhibitor that can modify the chromatin structure, potentially inhibiting PRDM10's ability to modulate gene expression through changes in histone acetylation. | ||||||